You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 64 No. 2, February 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (3)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Neurology
 •Drug Therapy
 •Adverse Effects
 •Psychiatry, Other
 •Alert me on articles by topic

Bilateral Deep Brain Stimulation of the Globus Pallidus to Treat Tardive Dyskinesia

Philippe Damier, MD, PhD; Stéphane Thobois, MD, PhD; Tatiana Witjas, MD; Emmanuel Cuny, MD; Philippe Derost, MD; Sylvie Raoul, MD, PhD; Patrick Mertens, MD, PhD; Jean-Claude Peragut, MD; Jean-Jacques Lemaire, MD, PhD; Pierre Burbaud, MD, PhD; Jean-Michel Nguyen, MD, PhD; Pierre-Michel Llorca, MD, PhD; Olivier Rascol, MD, PhD; for the French Stimulation for Tardive Dyskinesia (STARDYS) Study Group

Arch Gen Psychiatry. 2007;64(2):170-176.

Context  Tardive dyskinesia (TD) is a common and potentially disabling disorder induced by use of antipsychotic drugs for which medical treatment often gives disappointing results.

Objective  To assess the efficacy of bilateral deep brain stimulation of the internal part of the globus pallidus to treat severe TD.

Design  Prospective phase 2 multicenter study.

Setting  Six French university hospitals.

Patients  Patients with severe TD refractory to medical treatment were studied to evaluate the severity of abnormal involuntary movements before and after 6 months of bilateral globus pallidus deep brain stimulation. A 2-step open Fleming procedure was used to avoid unnecessary accrual of patients. A successful outcome was defined as a decrease of more than 40% in the main outcome measure at 6 months. The early stopping rule was invoked if the number of successful outcomes in 10 patients was fewer than 2, or 5 or more. A double-blind evaluation in the presence and absence of stimulation was performed at 6 months after surgery.

Main Outcome Measure  Change in score on the Extrapyramidal Symptoms Rating Scale.

Results  At 6 months after surgery, the Extrapyramidal Symptoms Rating Scale score had decreased compared with baseline by more than 40% (mean improvement, 61%; range, 44%-75%) in the first 10 patients included. In accord with the 2-step open Fleming procedure, we ended the trial at the first step and concluded that pallidal stimulation is an effective treatment for TD. The efficacy of the treatment was confirmed by a double-blind evaluation, with a mean decrease of 50% (range, 30%-66%) (P = .002) in the Extrapyramidal Symptoms Rating Scale score when stimulation was applied compared with the absence of stimulation. There were no marked changes in the patients' psychiatric status.

Conclusion  Although these results need to be confirmed in a larger group of patients with a longer follow-up, bilateral globus pallidus deep brain stimulation seems to offer a much-needed new treatment option for disabling TD.



Author Affiliations: Centre Hospitalier Universitaire de Nantes, Centre d’Investigation Clinique (Drs Damier and Raoul) and Pôle d’Information Médicale, d’Evaluation, et de Santé Publique (Dr Nguyen), and Institut National de la Santé Publique et de la Recherche Médicale, Unité 643 (Dr Damier), Nantes; Hôpital neurologique Pierre Wertheimer, Lyon (Drs Thobois and Mertens); Assistance Publique de Marseille, Service de neurochirurgie fonctionnelle et stéréotaxique, Marseille (Drs Witjas and Peragut); Hôpitaux de Bordeaux, Services de neurophysiologie clinique et de neurochirurgie, Bordeaux (Drs Cuny and Burbaud); Centre Hospitalier Universitaire de Clermont-Ferrand, Services de neurologie A (Dr Derost), Neurochirurgie (Dr Lemaire), and Psychiatrie A (Dr Llorca), Clermont-Ferrand; and Centre Hospitalier Universitaire de Toulouse, Service de Pharmacologie, Centre d’Investigation Clinique, Pôle de Neurosciences, Toulouse (Dr Rascol); France.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Metoclopramide, an Increasingly Recognized Cause of Tardive Dyskinesia
Kenney et al.
J Clin Pharmacol 2008;48:379-384.
FULL TEXT  

Deep Brain Stimulation for Tardive Dyskinesia
JWatch Psychiatry 2007;2007:1-1.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.